Conditions: Heart Failure, Congestive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 82
Healthy volunteers: no

Brief summary:
This exploratory proof of concept study will be conducted in patients with stable New York Heart Association (NYHA) Class II-III heart failure. The focus of the efficacy endpoints is to test the hypothesis that GSK716155 administration will increase glucose uptake and utilization in the myocardium, resulting in increased myocardial efficiency and increased exercise capacity. A positive result, defined as either statistically significant effects on one or more of the efficacy endpoints or as an overall signal suggesting a clinically relevant effect on myocardial physiology, would provide evidence for potential progression into further development in a chronic heart failure population.

Detailed description:

Arms:
arm 1: GSK716155 (3.75mg) arm 2: GSK716155 (15mg) arm 3: GSK716155 (30mg) arm 4: GSK716155-matcued placebo

Interventions: intervention 1: GSK716155 intervention 2: Placebo
Intervention descriptions: intervention 1: GSK716155 intervention 2: Placebo

Protocol document: